These nucleases provide a one-vendor strategy for preclinical research through GMP gene editing enzymes, engineered to be used in a variety of applications including electroporation, transfection and microinjection. These products are available at both
research and GMP quality grades, providing a seamless transition from research through clinical stage development and commercialization.
SpyFi® Cas9 Nuclease
The SpyFi® Cas9 Nuclease is designed for greater editing efficiency and reduced off-target effects without loss of on-target activity to help accelerate your CRISPR-Cas9 gene editing program. When used in combination with effective
guide, target site, and double-stranded DNA cut strategies, SpyFi Cas9 Nuclease can deliver comparable on-target editing and less off-target activity than wild-type SpCas9 nuclease. SpyFi Cas9 Nuclease can satisfy a wide range of
needs from basic research to clinical applications . A Drug Master File (DMF) is on file with the US FDA to streamline regulatory filings.
Eureca-V™ Nuclease is based on the proprietary MAD7®; nuclease developed by Inscripta®;. Eureca-V is categorized as a Class 2, Type V CRISPR-Cas nuclease. It shares key features common to this family of CRISPR nucleases, including:
- Targets broad array of T-rich PAM domains (YTTV preferred, TTTN functions)
- Requires a single crRNA to cut target DNA sequence
- Staggered double-strand break at cut site creates 5’ overhangs
This wild-type spCas9 nuclease is available for use in development work as well as standard GMP products for clinical studies. SpCas9 is ready to use for electroporation, transfections, or injection methods and is supported by an extensive QC panel at
research grade and GMP product levels.